US2014154277A1PendingUtilityA1
Pharmaceutical Compositions Comprising Soluble CD137
Est. expiryOct 19, 2031(~5.2 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 3/10A61P 37/06A61P 29/00C12N 2501/599A61P 19/02A61P 25/00A61K 38/177A61P 17/06A61K 38/1793A61K 40/416A61K 40/22A61K 40/11C12N 5/0637
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137 pos regulatory T cells. Also provided are pharmaceutical compositions for treating or preventing T-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble CD137 or CD137 pos regulatory T cells and a pharmaceutically-acceptable carrier.
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . A pharmaceutical composition for the treatment of a T-cell-mediated autoimmune disease comprising:
a therapeutically effective amount of soluble CD137; and a pharmaceutically-acceptable carrier.
14 . The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is in the form of an injectable suspension.
15 . The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is administered intravenously.
16 . The pharmaceutical composition of claim 13 , wherein the T-cell-mediated autoimmune disease is selected from the group consisting of type 1 diabetes, multiple sclerosis, psoriasis, and rheumatoid arthritis.
17 - 20 . (canceled)Join the waitlist — get patent alerts
Track US2014154277A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.